Insider Selling: Precision BioSciences, Inc. (NASDAQ:DTIL) Insider Sells 10,287 Shares of Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) insider J. Jefferson Smith sold 10,287 shares of the stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $4.79, for a total transaction of $49,274.73. Following the completion of the transaction, the insider now owns 87,440 shares of the company’s stock, valued at approximately $418,837.60. This represents a 10.53 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Precision BioSciences Price Performance

NASDAQ:DTIL opened at $5.08 on Friday. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.34. The firm has a market cap of $38.96 million, a PE ratio of 84.68 and a beta of 1.51. Precision BioSciences, Inc. has a 12 month low of $3.61 and a 12 month high of $19.43. The company’s 50-day moving average price is $5.46 and its two-hundred day moving average price is $7.96.

Analysts Set New Price Targets

Several research firms recently issued reports on DTIL. BMO Capital Markets raised shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price target for the company in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Precision BioSciences in a research report on Friday, January 10th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Precision BioSciences stock. Janus Henderson Group PLC grew its holdings in Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 702,069 shares of the company’s stock after purchasing an additional 68,943 shares during the quarter. Janus Henderson Group PLC owned about 9.15% of Precision BioSciences worth $6,322,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.